终末期肝病合并肌少症发生机制及干预防治研究进展

摘要/Abstract

摘要： 肌肉减少症是机体营养不良的重要表现之一,系指进行性和全身性的肌肉质量降低以及肌肉功能的丧失,其发生与进展与多种急慢性疾病互为因果,尤其在终末期肝病患者中普通存在,并与该类患者在院时长、生活质量低下、死亡等不良事件的发生率增加密切相关。近年来已得到该领域的广泛关注,并成为终末期肝病临床研究热点之一。本文通过对肌少症与终末期肝病相关研究进行综述,旨在为终末期肝病合并肌少症的治疗提供新的方向和证据,以期缩短住院时间、节约医疗资源、提高生活质量与生存率,改善终末期肝病患者临床结局。

关键词: 肌少症, 终末期肝病, 分子机制, 治疗方案

田亚文, 闫红林, 贺娜, 康改琳, 豆文丽, 赵梓棋, 孔繁娇, 任晫煦, 罗羽杉. 终末期肝病合并肌少症发生机制及干预防治研究进展[J]. 肝脏, 2023, 28(2): 253-256.

参考文献

[1] 马红琳,杨婧,金秋. 终末期肝病营养支持的研究现状. 临床肝胆病杂志,2022,01:215-219.
[2] Kang SH, Jeong WK, Baik SK, et al. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle,2018,9(5):860-870.
[3] Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med, 2011,27(3):337-339.
[4] Cruz-Jentoft AJ, Bahat G, Bauer J,et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing,2019,48(1):16-31.
[5] Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol, 2022,76(3):588-599.
[6] Dos Santos L, Cyrino ES, Antunes M, et al. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle,2017,8(2):245-250.
[7] Cawthon PM, Lui LY, Taylor BC, et al. Clinical definitions of sarcopenia and risk of hospitalization in community-dwelling older men: The osteoporotic fractures in men study. J Gerontol A Biol Sci Med Sci, 2017,72(10):1383-1389.
[8] 肖慧娟,韩涛. 肝硬化患者肌肉减少症的评估与干预策略. 中华肝脏病杂志,2021,03:199-203.
[9] Kamimura H, Sato T, Natsui K, et al. Molecular mechanisms and treatment of sarcopenia in liver disease: a review of current knowledge. Int J Mol Sci,2021,22(3):1425.
[10] 朱俊瑾,周佳琦,伍颖颖. 哺乳动物雷帕霉素靶蛋白复合物-1介导的自噬对骨代谢的调控. 国际口腔医学杂志,2020,01:84-89.
[11] Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell, 2012,149(2):274-293.
[12] Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol,2016 ,65(6):1232-1244.
[13] Le Grand F, Rudnicki MA. Skeletal muscle satellite cells and adult myogenesis. Curr Opin Cell Biol,2007,19(6):628-633.
[14] Wang Y, Pessin JE. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care,2013,16(3):243-250.
[15] Lee K, Ochi E, Song H, et al. Activation of AMP-activated protein kinase induce expression of FoxO1, FoxO3a, and myostatin after exercise-induced muscle damage. Biochem Biophys Res Commun,2015,466(3):289-294.
[16] Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol,2012,27(3):430-441.
[17] 刘钰懿,陈东风,颜綦先. 肝硬化肌少症的发病机制与诊疗现状. 临床肝胆病杂志,2022,01:191-195.
[18] Blonde-Cynober F, Aussel C, Cynober L. Abnormalities in branched-chain amino acid metabolism in cirrhosis: influence of hormonal and nutritional factors and directions for future research. Clin Nutr,1999,18(1):5-13.
[19] Jindal A, Jagdish RK. Sarcopenia: Ammonia metabolism and hepatic encephalopathy. Clin Mol Hepatol,2019,25(3):270-279.
[20] Davuluri G, Allawy A, Thapaliya S, et al. Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. J Physiol,2016,594(24):7341-7360.
[21] 盛莉,王琳,何周桃,等. 血清肌肉生长抑素、多配体蛋白聚糖-1对酒精性肝硬化患者肝癌发生风险及其预后评估价值. 创伤与急危重病医学,2021,04:253-256+261.
[22] Burks TN, Cohn RD. Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle,2011,1(1):19.
[23] Liu CA, Chang CY, Hsueh KW, et al. Migration/Invasion of malignant gliomas and implications for therapeutic treatment. Int J Mol Sci,2018,19(4):1115.
[24] 李云鹏,王新红,张德凯. 肠道菌群失调对肝硬化的影响. 临床肝胆病杂志,2019,04:887-890.
[25] Nishikawa H, Enomoto H, Nishiguchi S, et al. Liver cirrhosis and sarcopenia from the viewpoint of dysbiosis. Int J Mol Sci,2020,21(15):5254.
[26] Tuomisto S, Pessi T, Collin P, et al. Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol, 2014,14:40.
[27] Tyagi AM, Yu M, Darby TM, et al. The microbial metabolite butyrate stimulates bone formation via t regulatory cell-mediated regulation of WNT10B expression. Immunity,2018,49(6):1116-1131.e7.
[28] Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr, 2019,38(2):485-521.
[29] 中华医学会肝病学分会,中华医学会消化病学分会. 终末期肝病临床营养指南. 临床肝胆病杂志,2019,06:1222-1230.
[30] Hey P, Gow P, Testro AG, et al. Nutraceuticals for the treatment of sarcopenia in chronic liver disease. Clin Nutr ESPEN,2021,41:13-22.
[31] Tsien C, Davuluri G, Singh D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology,2015 ,61(6):2018-2029.
[32] Briskey D, Heritage M, Jaskowski LA, et al. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Therap Adv Gastroenterol,2016,9(4):463-472.
[33] Chen LH, Huang SY, Huang KC, et al. Lactobacillus paracasei?PS23 decelerated age-related muscle loss by ensuring mitochondrial function in SAMP8 mice. Aging (Albany NY),2019,11(2):756-770.
[34] Barton W, Penney NC, Cronin O, et al. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut,2018,67(4):625-633.